Global Leaders in Biologics
RTI Biologics Implements Recycling Initiative
- Jenny Highlander, APR
- Corporate Communications
ALACHUA, Fla. (March 29, 2012) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, announced today its commitment to reducing its environmental impact by implementing a company-wide recycling program. RTI is consolidating its waste management into a single company and expanding its current relationship with Stericycle, a leader in healthcare-related services that protects people and reduces risk.
RTI will be implementing Stericycle Sustainable Solutions®, which will manage regulated medical waste, solid and municipal waste, as well as recycling and other materials. This relationship makes RTI the first U.S. biotech firm to implement the service.
The expected benefits of the program are increased recycling and an overall waste management expense reduction. RTI will focus on converting increasing percentages of waste into recyclable goods. Widespread access to recycling equipment and employee education programs will lead to the proper classification and disposal of waste and other materials. The increase in recyclable goods is expected to help offset the expense of waste management, resulting in a significant cost savings to the company.
“By consolidating our waste management into a single company, we’ll be able to more efficiently monitor our waste streams and take proactive measures where we can to reduce our carbon footprint,” said Brian K. Hutchison, president and chief executive officer of RTI.
More than 30 recycling containers have been placed strategically throughout each of RTI’s owned buildings in Alachua, Fla., and recycling-based educational programming is being implemented to train staff on proper disposal.
About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biologics implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.
RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. The processes – the BioCleanse® Tissue Sterilization Process, Cancelle® SP DBM Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of millions of implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.
RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.